Overlapping use of tamoxifen and the antidepressant paroxetine (Paxil) significantly increases the risk of breast cancer mortality, data from a large cohort of breast cancer patients showed.
The excess breast-cancer mortality risk ranged as high as 91%, depending on the duration of simultaneous use, researchers reported online in BMJ.
Oops.
Androgen deprivation therapy (ADT) for prostate cancer can exacerbate cardiac risk factors and may increase the risk of heart attack and cardiac death, according to an advisory supported by four medical organizations.
Design, Setting, and Participants The Shanghai Breast Cancer Survival Study, a large, population-based cohort study of 5042 female breast cancer survivors in China. Women aged 20 to 75 years with diagnoses between March 2002 and April 2006 were recruited and followed up through June 2009. Information on cancer diagnosis and treatment, lifestyle exposures after cancer diagnosis, and disease progression was collected at approximately 6 months after cancer diagnosis and was reassessed at 3 follow-up interviews conducted at 18, 36, and 60 months after diagnosis. Annual record linkage with the Shanghai Vital Statistics Registry database was carried out to obtain survival information for participants who were lost to follow-up. Medical charts were reviewed to verify disease and treatment information.
Conclusion Among women with breast cancer, soy food consumption was significantly associated with decreased risk of death and recurrence.
Tofu anyone?
CRP concentration has continuous associations with the risk of coronary heart disease, ischaemic stroke, vascular mortality, and death from several cancers and lung disease that are each of broadly similar size. The relevance of CRP to such a range of disorders is unclear. Associations with ischaemic vascular disease depend considerably on conventional risk factors and other markers of inflammation.
Coffee May Reduce Risk of Deadly Prostate Cancer (Update1) – Bloomberg.com
So my pot a day habit is GOOD!
A rising PSA value within 18 months after radiation therapy predicts an increased risk of prostate cancer metastasis and mortality, data from a large retrospective study showed.
A very good interview with Dr. Stefan Gluck, medical oncologist at the Braman Family Breast Cancer Institute at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Breast cancer: The latest in research – Living – MiamiHerald.com
We look at the size of the cancer, the number of lymph nodes involved and the surgery. Those issues drive whether a woman will need radiation. Then the pathologist measures estrogen receptor, progesterone receptor and human epidermal growth receptor, the HER-2. The first two are good prognostic markers, whereas the HER-2 is a bad prognostic marker. If both good ones are positive, then it tends to be a less aggressive cancer and patients tend to do better over the years with fewer recurrences. The patient who has ER, PR negative breast cancer has many more recurrences, particularly in the first three to five years. The HER-2 doubles the recurrence rate if it is positive. The good news is we can counterbalance it with treatment. If a patient has an HER-2 positive breast cancer, we treat her with Herceptin. Herceptin is an immunotherapy because it’s an antibody and you infuse it every three weeks for one year. It decreases the recurrences by half. Then you have the cancer that is negative for ER, PR and HER-2. We call it triple negative breast cancer. The only thing we can use is chemotherapy.
High Intensity Focused Ultrasound.
lifeunderwriter.net 
You must be logged in to post a comment.